Welcome to our dedicated page for Microvision SEC filings (Ticker: MVIS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing MicroVision’s dense discussions of MEMS lasers, lidar calibration, and IP licensing agreements can feel like shining a diode into a fogbank. Each quarterly earnings report details shifting R&D burn rates and prototype milestones, while an 8-K may quietly announce a new OEM lidar evaluation. Missing one disclosure could upend your valuation model.
Stock Titan solves this problem. Our AI turns every MicroVision SEC filing into plain-English insights within seconds, whether you need the latest microvision quarterly earnings report 10-Q filing or a historical microvision annual report 10-K simplified. Real-time alerts surface microvision Form 4 insider transactions real-time, so you instantly see when executives buy or sell shares. Guided keyword flags highlight ADAS revenue commentary, patent additions, and cash-runway notes, letting you answer natural questions such as “How much is MicroVision spending on lidar R&D this quarter?” without scrolling through hundreds of pages.
Every document type is covered:
- Form 4 for microvision insider trading Form 4 transactions and microvision executive stock transactions Form 4
- 10-Q and AI-driven microvision earnings report filing analysis
- 10-K with section-by-section guidance—ideal for understanding microvision SEC documents with AI
- Proxy statements detailing microvision proxy statement executive compensation
- 8-K updates with microvision 8-K material events explained
Stop hunting through EDGAR tables; let Stock Titan’s expert summaries, ratio visualizations, and side-by-side quarter comparisons surface the trends that matter—licensing revenue growth, production-scale readiness, or insider sentiment—so you can act before the market does.
MTB Form 4 (filed 07/24/25): Sr. EVP Peter D’Arcy reports open-market sales of common shares.
- On 07/22/25, D’Arcy sold 1,937 shares at a $197.17 weighted-average price (range $196.62-$197.60) and 524 shares at $197.82 (range $197.61-$198.05), disposing of 2,461 shares in total.
- Estimated gross proceeds are roughly $0.49 million.
- Direct ownership declined from 11,780 to 9,319 shares, a ~21% reduction.
- He also holds 327 phantom stock units in a Supplemental 401(k) Plan; these are cash-settled and unchanged.
No shares were acquired, no options exercised, and the filing does not reference a Rule 10b5-1 plan. While executives may sell for personal reasons, such disposals can be viewed by investors as a modestly negative sentiment signal absent further context.
Jaguar Health (JAGX) has filed a Form S-3 to register up to 1,409,732 common shares for resale by existing investors. The stock derives from (i) 481,150 shares underlying 6 % convertible Replacement Notes issued 24 Jun 2025 (conversion price $5.535–$5.555, maturity 30 Jan 2026) and (ii) 928,582 shares issuable on cash or cash-less exercise of accompanying warrants (exercise price $2.70, 18-month term). At the 23 Jul 2025 close of $2.38 the warrant strikes sit 13 % above market while the note conversion price is >130 % above market. If fully converted/exercised the new shares would expand the current 1.914 million share float by roughly 74 %, creating a sizeable overhang.
The company will not receive proceeds from secondary sales; only a full cash exercise of all warrants could raise ~$2.5 million, earmarked for working capital. The filing follows several recent financings (March convertible notes and May registered direct offering) and occurs alongside an active GI-focused drug pipeline led by crofelemer (FDA-approved Mytesi, multiple Phase 2/3 programs, orphan designations) and the October 2024 U.S. launch of Gelclair for oral mucositis. While pipeline breadth offers optionality, near-term investors must weigh dilution risk and potential price pressure from selling stockholders against the modest capital infusion possible from warrant exercises.
FAQ
What is the current stock price of Microvision (MVIS)?
What is the market cap of Microvision (MVIS)?
What core technology does MicroVision utilize?
Which markets does MicroVision serve?
How does MicroVision generate revenue?
What differentiates MicroVision from other technology companies?
Can MicroVision's technology be adapted for multiple applications?
How important is intellectual property for MicroVision?
